Activation of Egr-1 promoter by DNA damaging chemotherapeutics

Details Activation of Egr-1 promoter by DNA damaging chemotherapeutics Activation of Egr-1 promoter by DNA damaging chemotherapeutics

2006-08-28

2011-10-11

Kelly, Robert M (Department: 1633)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C424S093100, C424S093200, C435S355000, C536S023100, C536S023500, C536S024100

Reexamination Certificate

active

08034791

ABSTRACT:
The present invention relates to methods of inducing expression of a polynucleotide encoding a therapeutic polypeptide, e.g., TNF-α, in a cell comprising contacting the cell with a construct comprising an Egr-1 promoter operably linked to a polynucleotide encoding the polypeptide, and at least one chemotherapeutic agent, wherein the chemotherapeutic agent induces expression of the polypeptide. The invention also relates to methods of inhibiting a neoplastic cell, comprising contacting the cell with a construct comprising an Egr-1 promoter operably linked to a polynucleotide encoding TNF-α and a chemotherapeutic agent. The present invention further relates to methods of inhibiting or reducing the growth of a tumor in a subject, comprising co-administering to the subject a construct comprising an Egr-1 promoter operably linked to a polynucleotide encoding TNF-α and a chemotherapeutic agent, wherein the co-administration inhibits or reduces the ability of the tumor to grow.

REFERENCES:
patent: 633626 (1899-09-01), Stone
patent: 4201767 (1980-05-01), Fullerton et al.
patent: 4370417 (1983-01-01), Hung et al.
patent: 4415732 (1983-11-01), Caruthers et al.
patent: 4458066 (1984-07-01), Caruthers et al.
patent: 4554101 (1985-11-01), Hopp
patent: 4587055 (1986-05-01), Regen
patent: 4664911 (1987-05-01), Uhr et al.
patent: 4677063 (1987-06-01), Mark et al.
patent: 4677064 (1987-06-01), Mark et al.
patent: 4684611 (1987-08-01), Schilperoort et al.
patent: 4769331 (1988-09-01), Roizman et al.
patent: 4792447 (1988-12-01), Uhr et al.
patent: 4797368 (1989-01-01), Carter et al.
patent: 4833080 (1989-05-01), Brent et al.
patent: 4835098 (1989-05-01), Orr et al.
patent: 4952500 (1990-08-01), Finnerty et al.
patent: 5045451 (1991-09-01), Uhr et al.
patent: 5128126 (1992-07-01), Boniver
patent: 5139941 (1992-08-01), Muzyczka et al.
patent: 5176617 (1993-01-01), Fischell et al.
patent: 5206152 (1993-04-01), Sukhatme
patent: 5252479 (1993-10-01), Srivastava
patent: 5264618 (1993-11-01), Felgner et al.
patent: 5288641 (1994-02-01), Roizman
patent: 5302523 (1994-04-01), Coffee et al.
patent: 5322783 (1994-06-01), Tomes et al.
patent: 5354855 (1994-10-01), Cech et al.
patent: 5359046 (1994-10-01), Capon et al.
patent: 5384253 (1995-01-01), Krzyzek et al.
patent: 5464765 (1995-11-01), Coffee et al.
patent: 5538877 (1996-07-01), Lundquist et al.
patent: 5538880 (1996-07-01), Lundquist et al.
patent: 5550318 (1996-08-01), Adams et al.
patent: 5563055 (1996-10-01), Townsend et al.
patent: 5571797 (1996-11-01), Ohno et al.
patent: 5578706 (1996-11-01), Ghetie et al.
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5589466 (1996-12-01), Felgner et al.
patent: 5591616 (1997-01-01), Hiei et al.
patent: 5610042 (1997-03-01), Chang et al.
patent: 5612318 (1997-03-01), Weichselbaum et al.
patent: 5652095 (1997-07-01), Taniguchi et al.
patent: 5656610 (1997-08-01), Shuler et al.
patent: 5672344 (1997-09-01), Kelley et al.
patent: 5686072 (1997-11-01), Uhr et al.
patent: 5702932 (1997-12-01), Hoy et al.
patent: 5736524 (1998-04-01), Content et al.
patent: 5759566 (1998-06-01), Poli et al.
patent: 5762904 (1998-06-01), Okada et al.
patent: 5767072 (1998-06-01), Vitetta et al.
patent: 5770581 (1998-06-01), Weichselbaum et al.
patent: 5780448 (1998-07-01), Davis et al.
patent: 5789215 (1998-08-01), Berns et al.
patent: 5795715 (1998-08-01), Livache et al.
patent: 5817636 (1998-10-01), Weichselbaum et al.
patent: 5871727 (1999-02-01), Curiel
patent: 5889136 (1999-03-01), Scaringe et al.
patent: 5925565 (1999-07-01), Berlioz et al.
patent: 5935819 (1999-08-01), Eichner et al.
patent: 5935935 (1999-08-01), Connelly et al.
patent: 5945100 (1999-08-01), Fick
patent: 5981274 (1999-11-01), Tyrrell et al.
patent: 5994136 (1999-11-01), Naldini et al.
patent: 5994624 (1999-11-01), Trolinder et al.
patent: 6013516 (2000-01-01), Verma et al.
patent: 6066624 (2000-05-01), Woo et al.
patent: 6069757 (2000-05-01), Arai et al.
patent: 6143290 (2000-11-01), Zhang et al.
patent: 6156736 (2000-12-01), Weichselbaum et al.
patent: 6228356 (2001-05-01), Glorioso et al.
patent: 6524832 (2003-02-01), Kufe et al.
patent: 6605712 (2003-08-01), Weichselbaum et al.
patent: 6899870 (2005-05-01), McDonnell et al.
patent: 7041653 (2006-05-01), Weichselbaum et al.
patent: 7214368 (2007-05-01), Rasmussen et al.
patent: 2001/0006954 (2001-07-01), Weichselbaum et al.
patent: 2003/0082685 (2003-05-01), Weichselbaum et al.
patent: 2004/0242523 (2004-12-01), Weichselbaum et al.
patent: 657111 (1995-06-01), None
patent: 0273085 (1988-07-01), None
patent: 0662137 (2005-05-01), None
patent: WO 92/11033 (1991-12-01), None
patent: WO 92/17598 (1992-10-01), None
patent: WO 94/06916 (1994-03-01), None
patent: WO 94/09699 (1994-05-01), None
patent: WO 95/06128 (1995-03-01), None
patent: WO 95/27071 (1995-10-01), None
patent: WO 96/33280 (1996-10-01), None
patent: 99/27908 (1999-06-01), None
patent: WO 99/32619 (1999-07-01), None
patent: WO 99/65515 (1999-12-01), None
patent: WO 00/44914 (2000-08-01), None
patent: WO 01/36646 (2001-05-01), None
patent: WO 01/68836 (2001-09-01), None
patent: WO 02/083653 (2002-10-01), None
Bold, R.J., et al., “Gemcitabine-Induced Programmed Cell Death (Apotosis) of Human Pancreatic Carcinoma Is Determined by Bcl-2 Content” Annals of Surgical Oncology, (Jun. 1999), vol. 6, No. 3, pp. 279-285.
Fritzell, J.A. et al., “Role of DNA mismatch repair in the cytotoxicity of ionizing radiation,” Cancer Research (1997) 57:5143-5147.
Arai, M. et al., “Mechanism of doxorubicin-induced inhibition of sarcoplasmic reticulum C12+-ATPase gene transcription,” Cir. Res. (2000) 86(1):8-14.
Joki, T. et al., “Modification of doxorubicin molecule enhanced the early growth response gene 1 promoter activity,” Jikeikai Med. J. (1996) 43(1):1-7.
Ohba, M. et al., “Production of hydrogen peroxide by transforming growth factor-beta-1 and its involvement in induction of egr-1 in mouse osteoblastic cells,” J. Cell Biol. (1994) 126(4)1079-1088.
Yu, J. et al., “Coactivating factors p300 and CBP are transcriptionally crossregulated by Egr1 in prostate cells, leading to divergent responses,” Molecular Cell (2004) 15:83-94 0.
Abate et al., “Redox regulation of Fos and Jun DNA-binding activity in vitro,” Science (1990) 249:1157-1161.
Abou-Shoer et al., “Flavonoids from Koelreuteria Henryi and other sources as protein-tyrosine kinase inhibitors,” J. Nat. Proc. (1993) 56(6):967-969.
Advani, S. et al., “Enhancement of replication of genetically engineered herpes simplex virus by ionizing radiation: a new paradigm for destrubtion of intractable tumors,” Gene Therapy (1998) 5:160-165.
Ainsworth, E.J. and Chase, H.B., “Effect of microbial antigens on irradiation mortality in ice,” Proc. Soc. Exp. Biol. Med. (1959) 102:483-485.
Al-Khodiary and Carr, “DNA repair mutants defining G2 checkpoint pathways inSchizosaccharomyces pombe,” The EMBO Journal (1992) 11(4):1343-1350.
Alberts et al., “A eucaryotic gene control region consists of a promoter plus regulatory DNA sequences,” Molecular Biology of the Cell (3rd Ed.) 423.
Alexander et al., “Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver,” J. Clin. Oncol. (1998) 16:1479-1489.
Alexandropoulos, K. et al., “v-Fps-responsiveness in the Egr-1 Promoter is Mediated by Serum Response Elements,” Nucleic Acids Research (1992) 20(9):2355-2359.
Andrews, G.K. et al., “The heat shock response in HeLa cells is accompanied by elevated expression of the c-fos proto-oncogene,” Mol. Cell. Biol. (1987) 7:3452-3458.
Angel, P. et al., “Induction of metallothionein and other mRNA species by carcinogens and tumor promoters in primary human skin fibroblasts,” Mol. Cell Biol. (1986) 6:1760-1766.
Angel, P. et al., “12-O-Tetradecanoyl-phorbol-13-acetate induction of the human collagenase gene is mediated by an inducible enhancer element loc

Affiliated with

Also associated with

Rating

Activation of Egr-1 promoter by DNA damaging chemotherapeutics does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Activation of Egr-1 promoter by DNA damaging chemotherapeutics, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Activation of Egr-1 promoter by DNA damaging chemotherapeutics will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4272538